Ware J. Anthony sold $1.8M of TRAX

Ware J. Anthony sold 39,265 shares of First Tracks Biotherapeutics, Inc. (TRAX) at $44.78 ($1.76M total) on 2026-09-02.

Original reporting
SEC EDGAR · Ware J. Anthony
Published Sep 4, 2026, 8:25 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 8:43 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TRAX
Bearish
medium confidence
Mentioned
$TRAX
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TRAXBearishLow
01

Why it matters

The director's sale reduces insider ownership, which may be interpreted as a bearish signal by the market.

02

Market read

Direct insider sale provides fresh material for traders; potential short‑term price impact.

03

What to watch

Sale could be for personal liquidity needs unrelated to confidence in the business.

Relevance 6/10Novelty 5/10Timing: filed Sep 4, 2026

Background

Form 4 filing reports insider transactions; this is the first public disclosure of the sale.

Company-level read

Ticker impact

$TRAXBearishMedium confidence
Context

Director Ware J. Anthony sold 39,265 shares for $1.76M, reducing his stake to 15,660 shares.

Expected impact

Modest downside pressure over the next few days.

Evidence & confidence

Large insider sale by a director, disclosed via Form 4, often leads to sell‑off as market interprets it as a negative signal.

Market effects

Minimal impact on the broader biotech sector; isolated insider transaction.

No significant regional effect.

Limited to investors tracking TRAX.

Counterpoint

Insider may be diversifying; sale does not necessarily reflect company fundamentals.

Key entities

  • First Tracks Biotherapeutics, Inc.

    Biotech firm listed under ticker TRAX.

  • Ware J. Anthony

    Director of First Tracks Biotherapeutics.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$TRAXHighAI 8/10

First Tracks Biotherapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

First Tracks Biotherapeutics, Inc. (TRAX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 First Tracks Biotherapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update • Announced ANB033 achieved a statistically significant and clinically meaningful protective effect on both gluten-induced intestinal damage and symptoms in Cohort

$TRAXMedAI 8/10

First Tracks Biotherapeutics (TRAX) Reports Positive ANB033 Celiac Cohort Results

First Tracks Biotherapeutics (TRAX) reported positive Phase 1b trial results for ANB033 in celiac disease, showing significant protection against gluten-induced damage. The company expects mucosal-healing data in Q1 2027 and eosinophilic esophagitis results in Q3 2027. It also anticipates late-stage trials for celiac disease and Phase 2 trials for vitiligo in 2027. The company raised $200 million in a private placement, bringing pro forma cash to $343 million.